TRU
MAIA

Steven M. Chaouki

Known title: President, US MarketsCIK: 0001776865

Steven M. Chaouki's purchase track record

How the stock did after each of Steven M. Chaouki's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
4
of 4 since August 1, 2022
Stock higher 6 months later
50%
3 months: 50%
Median 6-month return
-10.8%
3 months: -9.8%
Beat the S&P 500
25%
median -14.8% vs. index
PurchaseStockAmount3 months6 months
12/22/2025MAIA$50K+12.0%+3.8%
11/1/2024MAIA$56K-31.6%-25.4%
3/14/2024MAIA$41K+189.3%+148.1%
8/1/2022MAIA$25K-53.2%-39.9%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 5, 2026

TransUnion Faces Analyst Downgrades and Leadership Changes. TransUnion is navigating a period of strategic uncertainty following the exit of its CFO and the appointment of a new Strategy Chief. This internal shift coincides with lowered price targets from Goldman Sachs and Barclays, reflecting cautious sentiment among analysts. The stock is currently trading near significant support levels, highlighting the market's sensitivity to these corporate developments.

this person other insiders at TRU

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

MAIA Expands THIO-104 Trial to Spain, Portugal; Files Resale Prospectus. MAIA Biotechnology has broadened its pivotal Phase 3 THIO‑104 lung‑cancer trial to include Spain and Portugal after receiving regulatory clearance from the Spanish and Portuguese authorities. The company also filed a resale prospectus for 751,879 shares under its Clinical Trial Funding Agreement, providing additional capital for the study. These developments support the trial’s progression and expand patient access in key European markets.

this person other insiders at MAIA

Transaction History

TRU▼ Sell$84K
TRU▼ Sell$687K
TRU▼ Sell$80K
TRU▼ Sell$726K
TRU▼ Sell$354K
TRU▼ Sell$1.1M
TRU▲ Buy$0
TRU▼ Sell$360K
TRU▼ Sell$350K
TRU▼ Sell$383K
TRU▼ Sell$835K
TRU▲ Buy$0
TRU▲ Buy$0
TRU▼ Sell$86K
MAIA▲ Buy$50K
TRU▼ Sell$84K
TRU▼ Sell$80K
TRU▼ Sell$83K
TRU▼ Sell$86K
TRU▼ Sell$457K
TRU▼ Sell$148K
TRU▼ Sell$91K
TRU▼ Sell$87K
TRU▼ Sell$85K
TRU▼ Sell$83K
TRU▼ Sell$83K
TRU▼ Sell$92K
TRU▲ Buy$0
TRU▲ Buy$0
TRU▼ Sell$143K
TRU▼ Sell$96K
TRU▼ Sell$94K
TRU▼ Sell$151K
TRU▼ Sell$158K
TRU▼ Sell$0
MAIA▲ Buy$56K
TRU▼ Sell$96K
TRU▼ Sell$234K
TRU▼ Sell$156K
TRU▼ Sell$90K
TRU▼ Sell$74K
TRU▼ Sell$128K
TRU▼ Sell$130K
TRU▼ Sell$144K
MAIA▲ Buy$41K
TRU▼ Sell$139K
TRU▲ Buy$0
TRU▲ Buy$0
TRU▼ Sell$377K
TRU▼ Sell$91K
TRU▼ Sell$105K
TRU▼ Sell$84K
TRU▼ Sell$73K
TRU▼ Sell$76K
TRU▼ Sell$70K
TRU▼ Sell$67K
TRU▼ Sell$125K
TRU▲ Buy$0
TRU▲ Buy$0
TRU▼ Sell$101K
TRU▼ Sell$59K
MAIA▲ Buy$25K
MAIA▼ Sell—
TRU▲ Buy$0
TRU▼ Sell$864K
TRU▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.